| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,173 | 3,286 | 3,333 | 3,653 | 3,791 | 3,643 | 3,560 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,217 | 2,383 | 2,401 | 2,724 | 2,776 | 2,754 | 2,536 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 956 | 903 | 933 | 930 | 1,016 | 889 | 1,024 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % | 23 % | 26 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 101 | 187 | 231 | 219 | 222 | 223 | 223 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 | 509 | 659 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 | 95 | 100 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 | 9.90 | 13.44 |
Mankind Pharma
Mankind Pharma
2,525.10
-6.90
(-0.27%)
Market Cap
1,04,285.61 Cr
PE Ratio
53.94
Volume
5,24,763.00
Day High - Low
2,572.00 - 2,510.60
52W High-Low
2,716.50 - 1,909.70
There are 4 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
1,04,285.61 Cr
EPS
46.35
PE Ratio
53.94
PB Ratio
6.41
Book Value
394.69
EBITDA
3,487.60
Dividend Yield
0.04 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
13.77
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Mankind Pharma achieved a 72.14% reduction in carbon emissions for FY 2025-26. The company processed 4,503 MT of plastic waste for recycling.
Mankind Pharma schedules 35th AGM on August 4, 2026 via VC/OAVM. FY2026 consolidated revenue rose 17% YoY to ₹14,278 crores; key resolutions include director re-appointments and cost auditor ratification.
Jefferies Maintains Buy on Mankind Pharma, TP ₹3,0001 day ago
Jefferies reiterates Buy rating on Mankind Pharma with a target price of ₹3,000, citing early turnaround signs and preferring it over Dr. Reddy's and Cipla.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,935.50 | #1 4,64,391.28 | 40.42 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 69.33 | |
6,836.00 | 1,81,474.32 | 70.42 | 10,560.00 | 8.73 | 2,520 | 13.44 | 57.88 | |
4,901.50 | 1,65,889.03 | 77.50 | 13,886.20 | 20.34 | 2,138 | -26.91 | 76.03 | |
1,439.40 | 1,16,281.25 | 30.16 | 29,044.60 | 2.24 | 3,870 | -55.32 | 56.29 | |
1,150.80 | 1,15,797.41 | 22.58 | 26,719.70 | 13.65 | 5,242 | 7.82 | 65.75 | |
2,496.30 | 1,14,138.96 | #1 21.37 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 68.54 | |
2,525.10 | #7 1,04,285.61 | #7 53.94 | #7 14,277.60 | #6 12.03 | #9 1,750 | #2 31.75 | 58.02 | |
1,244.30 | 1,03,857.87 | 25.49 | 35,058.60 | 3.90 | 4,158 | -86.05 | 35.49 | |
1,564.70 | 90,029.38 | 26.31 | 33,384.70 | 3.21 | 3,376 | 1.99 | 56.89 | |
1,537.80 | 83,019.15 | 91.21 | 6,867.80 | #1 22.01 | 890 | 21.18 | 64.70 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.03 %
Net Income Growth
-12.80 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
-14.63 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 13,256 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 | 6,954 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 | 655 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 | 2,145 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 | 0 |
| Total Equity & Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 | 6,507 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 | 5,011 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 | 16,300 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Share Capital | 40 | 40 | 40 | 40 | 41 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % | 72.66 % | 72.66 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % | 11.34 % | 10.24 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % | 13.25 % | 14.46 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % | 1.52 % | 1.39 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % | 1.23 % | 1.25 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 04 Aug 2026 |  Annual General Meeting | NA | 04 Aug 2026 | 2,485.30 | 2,531.35 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,504.25 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,432.40 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.50 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,384.70 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.50 | 2,537.80 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,432.40 | 2,369.35 |
| 03 Feb 2026 | Quarterly Result Announcement | NA | 03 Feb 2026 | 2,261.20 | 2,063.80 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 2,361.90 | 2,496.35 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
5 hrs ago
5 hrs agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication7 hrs ago
7 hrs agoBusiness Responsibility and Sustainability Reporting (BRSR)23 hrs ago
23 hrs agoRegulation 53 (1) Annual Report.1 day ago
1 day agoReg. 34 (1) Annual Report.1 day ago
1 day agoNotice Of 35Th AGM1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoIntimation Of Date Of AGM10 days ago
10 days agoClosure of Trading WindowJun 25, 2026
Jun 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 15, 2026
Jun 15, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 08, 2026
Jun 08, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 08, 2026
Jun 08, 2026Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2026
Jun 02, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-AcquisitionMay 19, 2026
May 19, 2026Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Credit RatingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2026
May 08, 2026Board Meeting Intimation for Inter Alia Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 And Realignment Of Security Cover Provided In Respect Of ExistiMay 07, 2026
May 07, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 22, 2026
Apr 22, 2026Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Apr 16, 2026
Apr 16, 2026Announcement under Regulation 30 (LODR)-RestructuringApr 13, 2026
Apr 13, 2026Board Meeting Outcome for Outcome Of Board MeetingApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 16, 2026
Mar 16, 2026Clarification Submitted By Mankind Pharma LimitedFeb 27, 2026
Feb 27, 2026Clarification sought from Mankind Pharma LtdFeb 27, 2026
Feb 27, 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Credit RatingFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Feb 18, 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 16, 2026
Feb 16, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2026
Feb 03, 2026Compliances-Reg. 54 - Asset Cover details Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2026
Feb 03, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 59.01
ATR(14)
Less Volatile 67.89
STOCH(9,6)
Neutral 53.58
STOCH RSI(14)
Neutral 28.58
MACD(12,26)
Bullish 1.63
ADX(14)
Strong Trend 30.96
UO(9)
Bearish 43.75
ROC(12)
Downtrend And Accelerating -0.25
WillR(14)
Neutral -34.45
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(3 Years, 2 Months, 1 Day)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
